ELF1 - Molecular mechanisms of a novel transcription factor with broad antiviral activity

ELF1 - 具有广泛抗病毒活性的新型转录因子的分子机制

基本信息

  • 批准号:
    10162699
  • 负责人:
  • 金额:
    $ 16.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-06-18 至 2021-12-31
  • 项目状态:
    已结题

项目摘要

PARENT GRANT-PROJECT SUMMARY The primary goal of this R01 proposal is to characterize the interferon-stimulated gene E74-like ETS transcription factor 1 (ELF1), in vivo and in vitro, regarding its role in restricting virus infections. Although hundreds of interferon-stimulated genes (ISGs) execute the antiviral function of interferon (IFN), for the vast majority, the molecular mechanisms remain a mystery. Understanding the mechanisms by which host factors inhibit viral infections may lead to novel antiviral strategies. The project is founded on our recent published discovery that ELF1 exhibits direct antiviral action in inhibiting influenza A virus. Since that initial discovery, our preliminary data show that ELF1 acts after multiple rounds of viral replication and is broadly antiviral. In epithelial cells, ELF1 transcriptionally regulates a vast program of hundreds of genes mostly distinct from those regulated by IFN. ELF1 does not feed forward to produce IFN, and retains its strong antiviral potential even in the absence of further IFN signaling. Intriguingly, at least part of this program confers protection to neighboring cells. Finally, we show that local knockdown of murine Elf1 during IAV infection significantly increases viral lung titers, morbidity, and mortality in vivo. These results opened the door to propose a novel concept for ELF1's role in the IFN response: that this transcription factor is a novel regulator of inflammation and innate antiviral immunity. In addition, our data raise the exciting possibility that ELF1's antiviral program continues protecting cells from viral infections even in the refractory phase post IFN exposure, or when IFN signaling is abrogated by viral antagonists. The main technical innovation of this proposal is the use the versatile tool of confocal high-content imaging to study sub-cellular signaling events during viral infections. Completion of our aims will have major impact on the field, by characterizing a novel transcriptional antiviral program that is as broad and potent, but distinct from IFN.
项目概要 本R 01提案的主要目标是表征干扰素刺激的基因E74样ETS转录 因子1(ELF 1),在体内和体外,关于其在限制病毒感染的作用。虽然每天有数百个 干扰素刺激基因(ISG)执行干扰素(IFN)的抗病毒功能,对于绝大多数, 分子机制仍然是个谜。了解宿主因子抑制病毒的机制 感染可能导致新的抗病毒策略。该项目是建立在我们最近发表的发现, ELF 1在抑制甲型流感病毒方面表现出直接的抗病毒作用。从最初的发现开始,我们的初步数据 表明ELF 1在多轮病毒复制后起作用,并且具有广泛的抗病毒性。在上皮细胞中,ELF 1 转录调节数百个基因的庞大程序,大多数与IFN调节的基因不同。 ELF 1不前馈以产生IFN,并且即使在缺乏IFN的情况下也保留其强的抗病毒潜力。 更多IFN信号有趣的是,这个程序至少有一部分可以保护邻近的细胞。最后我们 显示在IAV感染期间鼠Elf 1局部敲低显著增加病毒肺滴度、发病率 和体内死亡率。这些结果为ELF 1在IFN-γ中的作用提出了一个新的概念。 反应:这种转录因子是一种新型的炎症和先天性抗病毒免疫调节因子。在 此外,我们的数据提出了一种令人兴奋的可能性,即ELF 1的抗病毒程序继续保护细胞免受病毒感染。 即使在IFN暴露后的难治期,或当IFN信号被病毒抑制时, 对手。本方案的主要技术创新点是使用了多功能的共焦高含量成像工具 成像以研究病毒感染期间的亚细胞信号传导事件。实现我们的目标将有重大意义。 对该领域的影响,通过表征一种新的转录抗病毒程序,这是广泛和有效的,但 不同于IFN。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Meike Dittmann其他文献

Meike Dittmann的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Meike Dittmann', 18)}}的其他基金

ELF1 - Molecular mechanisms of a novel transcription factor with broad antiviral activity
ELF1 - 具有广泛抗病毒活性的新型转录因子的分子机制
  • 批准号:
    10200184
  • 财政年份:
    2020
  • 资助金额:
    $ 16.58万
  • 项目类别:
ELF1 - Molecular mechanisms of a novel transcription factor with broad antiviral activity
ELF1 - 具有广泛抗病毒活性的新型转录因子的分子机制
  • 批准号:
    10318970
  • 财政年份:
    2019
  • 资助金额:
    $ 16.58万
  • 项目类别:
ELF1 - Molecular mechanisms of a novel transcription factor with broad antiviral activity
ELF1 - 具有广泛抗病毒活性的新型转录因子的分子机制
  • 批准号:
    10533751
  • 财政年份:
    2019
  • 资助金额:
    $ 16.58万
  • 项目类别:
Intrinsic and innate barriers to respiratory virus infections
呼吸道病毒感染的内在和先天障碍
  • 批准号:
    9415534
  • 财政年份:
    2017
  • 资助金额:
    $ 16.58万
  • 项目类别:
Intrinsic and innate barriers to respiratory virus infections
呼吸道病毒感染的内在和先天障碍
  • 批准号:
    9014078
  • 财政年份:
    2016
  • 资助金额:
    $ 16.58万
  • 项目类别:

相似海外基金

cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
cGAS-STING 通路靶向具有 CD46 趋向性和 AFP 启动子的复制腺病毒条件性复制限制用于治疗肝细胞癌
  • 批准号:
    10436626
  • 财政年份:
    2021
  • 资助金额:
    $ 16.58万
  • 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10557162
  • 财政年份:
    2021
  • 资助金额:
    $ 16.58万
  • 项目类别:
Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
  • 批准号:
    21K08199
  • 财政年份:
    2021
  • 资助金额:
    $ 16.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10330464
  • 财政年份:
    2021
  • 资助金额:
    $ 16.58万
  • 项目类别:
Structural characterization of nucleoprotein cores of human adenoviruses
人腺病毒核蛋白核心的结构表征
  • 批准号:
    9807741
  • 财政年份:
    2019
  • 资助金额:
    $ 16.58万
  • 项目类别:
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2018
  • 资助金额:
    $ 16.58万
  • 项目类别:
    Discovery Grants Program - Individual
The therapeutic strategies with augmented replications of oncolytic adenoviruses for malignant mesothelioma
溶瘤腺病毒增强复制治疗恶性间皮瘤的治疗策略
  • 批准号:
    18K15937
  • 财政年份:
    2018
  • 资助金额:
    $ 16.58万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2017
  • 资助金额:
    $ 16.58万
  • 项目类别:
    Discovery Grants Program - Individual
Research on detection of novel adenoviruses by genetic methods
新型腺病毒的基因检测研究
  • 批准号:
    16K09118
  • 财政年份:
    2016
  • 资助金额:
    $ 16.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploring the effects of nutrient deprivation on T cells and oncolytic adenoviruses, in order to create immune activators for tumour therapy
探索营养剥夺对 T 细胞和溶瘤腺病毒的影响,以创造用于肿瘤治疗的免疫激活剂
  • 批准号:
    1813152
  • 财政年份:
    2016
  • 资助金额:
    $ 16.58万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了